Business Context and Reporting Period
Company: PAVmed Inc. (PAVM)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: PAVmed is a diversified commercial-stage life sciences company operating through a shared services model with independently financed subsidiaries. Key subsidiaries include Lucid Diagnostics (cancer prevention diagnostics, specifically the EsoGuard test) and Veris Health (digital health platform for cancer care). PAVmed also maintains a medical device pipeline including the PortIO device and endoscopic imaging technology.
Key Structural Change: PAVmed deconsolidated Lucid Diagnostics on September 10, 2024, due to a loss of controlling financial interest. Lucid is now accounted for as an equity method investment at fair value. PAVmed regained compliance with Nasdaq listing requirements via a 1-for-30 reverse stock split effective January 2, 2026.
Key Financial Metrics
| Metric (in thousands) | Year Ended Dec 31, 2025 | Year Ended Dec 31, 2024 |
|---|---|---|
| Revenue | $71 | $2,995 |
| Operating Loss | $(21,806) | $(44,487) |
| Net Income (Loss) Attributable to PAVmed Common Stockholders | $(3,774) | $31,966 |
| Cash and Cash Equivalents (End of Period) | $1,538 | $1,185 |
| Net Cash Used in Operating Activities | $(5,206) | $(33,554) |
| Total Assets | $38,812 | $30,660 |
| Total Liabilities | $16,512 | $37,693 |
| Working Capital | $(12,280) | $(33,282) |
Note: 2024 results included a one-time $72.3 million gain on the deconsolidation of Lucid Diagnostics. 2025 revenue is primarily from Veris Health subscriptions, as Lucid revenue is no longer consolidated.
Material Changes vs. Prior Period
- Revenue Decline: Revenue dropped 98% to $0.1 million, primarily because Lucid Diagnostics' operations were deconsolidated in late 2024. The 2024 figure included Lucid revenue through September 10, 2024.
- Expense Reduction: Operating expenses decreased significantly (e.g., Sales & Marketing down $10.7M, G&A down $8.2M) due to the exclusion of Lucid's operating costs post-deconsolidation.
- Debt Restructuring: In February 2026 (subsequent to year-end), PAVmed refinanced its September 2022 Senior Convertible Note into a new $15.0 million "2026 Note" with a 15% interest rate and maturity in 2029. This followed a $30 million Series D Preferred Stock offering.
- Equity Method Investment: The fair value of PAVmed's investment in Lucid Diagnostics increased to $34.1 million (from $25.6 million in 2024), resulting in an $8.5 million unrealized gain recognized in 2025.
- Management Fee Income: PAVmed recognized $13.8 million in management fee income from Lucid in 2025, up from $3.9 million in 2024, reflecting increased fees under the Management Services Agreement.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Recent Developments
- Lucid Diagnostics: Lucid secured a contract with the U.S. Department of Veterans Affairs (VA) in January 2026. It also received a positive coverage policy from Highmark Blue Cross Blue Shield in New York. Lucid raised $27.0 million in a September 2025 public offering.
- Veris Health: Launched the commercial phase of a strategic partnership with The Ohio State University Comprehensive Cancer Center in October 2025. Veris raised $2.5 million in June 2025.
- Medical Devices: PAVmed hired a Chief Business Officer for Medical Devices in March 2026 and licensed endoscopic imaging technology from Duke University in February 2026.
Risks and Contingencies
- Going Concern: The independent auditor has issued an explanatory paragraph expressing substantial doubt about PAVmed's ability to continue as a going concern. The company has a significant working capital deficiency and recurring operating losses. Continued operations depend on raising additional capital and managing costs.
- Reimbursement Uncertainty: Commercialization of the EsoGuard test depends heavily on securing Medicare coverage. While a Local Coverage Determination (LCD) reconsideration process is ongoing, there is no assurance of approval.
- Debt Covenants: The new 2026 Note requires maintaining a minimum cash balance of $5 million (increasing to $8 million in July 2026) and specific debt-to-market cap ratios. Failure to meet these could trigger default.
- Dilution: Significant dilution occurred via the Series D Preferred Stock conversion (4.6 million shares) and potential future exercises of warrants.
Investor Verification Checklist
- Going Concern Status: Verify the company's ability to raise capital to meet the $5M-$8M minimum cash covenant required by the new 2026 Note.
- Lucid Diagnostics Performance: Monitor Lucid's independent financial results and the status of the Medicare LCD reconsideration for EsoGuard, as PAVmed's value is heavily tied to its equity stake in Lucid.
- Debt Service: Confirm the company's ability to service the $15M 2026 Note (15% interest) and the $2.25M annual cash interest payments.
- Revenue Visibility: Assess the growth trajectory of Veris Health subscription revenue, which is now the primary consolidated revenue stream.
- Warrant Exercise: Track the exercise of Series D warrants, which could provide an additional $30 million in proceeds if Medicare coverage for EsoGuard is secured.